Red blood cell–derived nanoerythrosome for antigen delivery with enhanced cancer immunotherapy-Reference-Cited by-同舟云学术

Red blood cell–derived nanoerythrosome for antigen delivery with enhanced cancer immunotherapy

Published:2019-10-04 Issue:10 Volume:5 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Han Xiao¹^ORCID,Shen Shufang¹^ORCID,Fan Qin¹,Chen Guojun²,Archibong Edikan³,Dotti Gianpietro³,Liu Zhuang¹,Gu Zhen²⁴^ORCID,Wang Chao¹^ORCID

Affiliation:

1. Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-based Functional Materials and Devices, Soochow University, Suzhou, Jiangsu 215123, China.

2. Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA.

3. Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

4. California NanoSystems Institute, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095, USA.

Abstract

We developed an antigen delivery system based on the nanoerythrocyte vehicle combined with anti–PD-L1 for cancer immunotherapy.

Funder

the Program for Jiangsu Specially-Appointed Professors

startup supports of Soochow University

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference42 articles.

1. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations